Oraqix

PreclinicalSmall molecule

JJoanneum Research Forschungsgesellschaft mbH

Oraqix is one of 43 small molecule programs targeting Pilot Study. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pilot StudyCompleted

DrugCompleted

Pilot StudyPreclinical

Completed

DrugPreclinical

Completed

Competition

Competitive Landscape

29 competitors in Drug

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

1 2

Inderal

WWyeth-Lederle Vaccines

Approved

1 3

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 4

Ketalar

AAultman Health Foundation

Phase 3

1 5

Keytruda

Merck & Co.

Phase 2

1 6

Lenvima

Eisai

Phase 2

1 7

Pepcid

KKenvue Brands

Phase 1

7 8

BAY 987519

Bayer

Phase 1

1 9

Sovaldi

Gilead

Preclinical

2 10

Prostigmin

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug1 trial

An Exploratory Study in Healthy Volunteers to Identify Factors Influencing Bioequivalence Studies on Moderately Lipophilic Drugs Using Dermal Open Flow Microperfusion (dOFM)

Completed·JJoanneum Research Forschungsgesellschaft mbH·N/A·NCT04050826·20 enrolled

Pilot Study1 trial

An Exploratory Pilot Study in Healthy Volunteers to Assess the Parameters for the Design of Bioequivalence Studies on Moderately Lipophilic, Moderately to Highly Protein Bound Drugs Using Dermal Open Flow Microperfusion (dOFM)

Completed·JJoanneum Research Forschungsgesellschaft mbH·N/A·NCT03613207·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Oraqix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oraqix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oraqix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Joanneum Research Forschungsgesellschaft mbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJoanneum Research Forschungsgesellschaft mbH